Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Fortress Biotech will share a corporate overview and hold one-on-one investor meetings at the September 2026 H.C. Wainwright conference.
Rhea-AI Summary
Fortress Biotech (FBIO) will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. Chairman, President and CEO Lindsay A. Rosenwald, M.D., is scheduled to deliver the presentation, which will be available for on-demand viewing to conference attendees starting Friday, September 11, 2026, at 7:00 a.m. ET.
Fortress will also participate in one-on-one meetings during the conference, which takes place September 14–16, 2026. The company highlights a portfolio of marketed prescription products and development programs across oncology, dermatology and rare diseases, advanced through majority-owned entities and minority holdings, and supported by partnerships with leading academic and biopharmaceutical organizations.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on Friday, September 11, 2026, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference taking place September 14-16, 2026.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.
Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When will Fortress Biotech’s presentation be available to viewers at the H.C. Wainwright conference?
The corporate overview presentation will be available for on-demand viewing by conference attendees starting on Friday, September 11, 2026, at 7:00 a.m. ET.
When is the H.C. Wainwright 28th Annual Global Investment Conference taking place, and how is Fortress participating?
The conference will be held from September 14–16, 2026. Fortress Biotech plans to attend and participate in one-on-one meetings during the event.